Bispecific antibodies are one of the most active areas of cancer research, and pharmaceutical companies are busy striking deals to add them to their pipelines. One of the most talked about drugs at ...

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers. New research presented at ASCO GI positions ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. In fact ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this episode of Meeting Mic, we bring you pearls and ...

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today ...

Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference. Announcement of the oral presentation of ReSPECT-LM clinical trial ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning. Oncology professionals ...

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, ...

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral ...

Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial We retrospectively ...